Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) 

Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse IL-7Rα/CD127. Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) blocks IL-7 signaling. Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) can be used for the researches of cancer,infection, inflammation, immunology, cardiovascular and metabolic disease, such as abdominal aortic aneurysms, helicobacter felis-induced gastritis and diabetes^{[1][2][3][4][5]}.

IL-7Rα/CD127

The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) (20 μg/mouse, i.p., daily from day 2 to 14) delays the progression of abdominal aortic aneurysms companied with Elastase (HY-P2974) in mice^[1].
Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) (250 μg twice a week for 6-8 weeks for prevention treatment, 500 μg twice a week for 8 weeks from 5 to 7 week for reversal treatment, i.p.) prevents and revers alopecia areata in C3H/HeJ skin-grafted mice models of alopecia areata^[2].
Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) (5 mg, i.p., every seventh day for 3 months) inhibits the development of gastritis in helicobacter felis-induced gastritis mice models^[3].
Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) (500 μg at the first week and 125 μg for 6 weeks, i.p., twice a week) reduces post-myocardial infarction-induced atherosclerotic plaque inflammation in ApoE-/- mice^[4].
Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) (0.5 mg, i.p., twice a week for 5-14 weeks) prevents and revers diabetes in non-obese diabetic mice models^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

16197  [NCBI]

P16872

ELISA, FACS, Functional assay, Research in vivo

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

Liquid

Colorless to light yellow

[Anti-Mouse IL-7Rα/CD127 Antibody (A7R34)]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Xu S, et al. Deficiency of IL-7R attenuates abdominal aortic aneurysms in mice by inhibiting macrophage polarization towards M1 phenotype through the NF-κB pathway. Mol Med. 2025 Apr 16;31(1):138.  [Content Brief]

  [2]. Dai Z, et al. Blockade of IL-7 signaling suppresses inflammatory responses and reverses alopecia areata in C3H/HeJ mice. Sci Adv. 2021 Apr 2;7(14):eabd1866.  [Content Brief]

  [3]. Ohana M, et al. A critical role for IL-7R signaling in the development of Helicobacter felis-induced gastritis in mice. Gastroenterology. 2001 Aug;121(2):329-36.  [Content Brief]

  [4]. Mihailovic PM, et al. IL-7R blockade reduces post-myocardial infarction-induced atherosclerotic plaque inflammation in ApoE-/- mice. Biochem Biophys Rep. 2019 May 13;19:100647.  [Content Brief]

  [5]. Penaranda C, et al. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12668-73.  [Content Brief]